Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Brown JR, Walker SR, Heppler LN, Tyekucheva S, Nelson EA, Klitgaard J, Nicolais M, Kroll Y, Xiang M, Yeh JE, Chaudhury M, Giaccone ZT, Fernandes SM, Jacobsen ED, Fisher DC, Freedman AS, Davids MS, Supko JG, Wu C, Frank DA. Brown JR, et al. Among authors: jacobsen ed. Am J Hematol. 2021 Apr 1;96(4):E95-E98. doi: 10.1002/ajh.26084. Epub 2021 Jan 11. Am J Hematol. 2021. PMID: 33373063 Free PMC article. Clinical Trial. No abstract available.
Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Armand P, et al. Among authors: jacobsen ed. Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25. doi: 10.1016/j.bbmt.2008.01.008. Biol Blood Marrow Transplant. 2008. PMID: 18342784 Free PMC article.
Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.
Armand P, Gannamaneni S, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Antin JH. Armand P, et al. Among authors: jacobsen ed. J Clin Oncol. 2008 Dec 10;26(35):5767-74. doi: 10.1200/JCO.2008.17.7279. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001324 Free PMC article.
(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.
Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS, LaCasce AS, Jacobsen ED, Fisher DC, Soiffer RJ, Alyea EP, Koreth J, Freedman AS. Abou-Nassar KE, et al. Among authors: jacobsen ed. Bone Marrow Transplant. 2011 Dec;46(12):1503-9. doi: 10.1038/bmt.2010.339. Epub 2011 Jan 24. Bone Marrow Transplant. 2011. PMID: 21258420 Free PMC article. Clinical Trial.
108 results